Pfizer (PFE) Signs Medicus Oncology Deal, Is The Stock Still Undervalued?
Pfizer (PFE) just signed a wide-ranging co-development and license agreement with Medicus Pharma for PF-08046031, an early clinical-stage antibody-drug conjugate. The deal puts a new oncology-focused asset on the radar for shareholders.
The Pfizer share price has slipped over the past week, with a 7-day share price return of 2.66% and a 1-day move down 2.32%. However, the 30-day and 90-day share price returns of 3.85% and 8.55% suggest improving momentum as investors weigh deals like the Medicus partnership alongside COVID-19 vaccine approvals, conference appearances and dividend discussions.
Scan how Pfizer compares with a hand-picked group of healthcare heavyweights and income ideas using the 49 high quality undervalued stocks as a starting point for deeper research.
Pfizer shares have bounced over the past quarter yet still trade at a steep discount to one estimate of intrinsic value. Do the current risks around patent losses and pipeline execution still leave more upside than downside for new buyers?
Most Popular Narrative: 5% Undervalued
Pfizer's most followed narrative pegs fair value near $29.19 per share, only modestly above the last close at $27.79, which keeps the valuation debate finely balanced.
Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.
Want to see how this oncology and obesity blueprint is wired together? The fair value hinges on shrinking top line, fatter margins, and a richer earnings multiple. Curious which revenue path and profit profile have to line up for that outcome to work? The full narrative spells out the exact trade offs.
Result: Fair Value of $29.19 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, that fair value story can unravel if the planned shift toward higher margins stalls, or if key patent expirations hit revenue harder than expected.
Find out about the key risks to this Pfizer narrative.
Another View: What Pfizer’s P/E Is Telling You
Pfizer might look inexpensive on one fair value estimate, yet the P/E story points in a very different direction. The stock trades on 36.5x earnings, which is more than double the US Pharmaceuticals industry at 16.2x and above its own fair ratio of 28.3x.
That gap suggests investors are already paying up for future progress. As a result, the risk is that any stumble in execution leaves little room for error. If the market slowly leans back toward that 28.3x fair ratio, how much conviction would you need to keep paying today’s richer multiple?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling conflicted by the mix of Pfizer upside and pressure points in this article? Move fast, check the full data set yourself, then weigh the 2 key rewards and 4 important warning signs.
Looking for more Pfizer investment ideas?
Do not stop with a single view on Pfizer when a few extra minutes with the Simply Wall Street Screener could surface opportunities you regret missing later.
- Target reliable cash returns by scanning income-focused stocks through the 6 dividend fortresses that can complement or contrast Pfizer in your portfolio.
- Hunt for mispriced quality by running the 17 high quality undiscovered gems and spotting businesses the market may not be paying full attention to yet.
- Reduce portfolio stress by checking the 82 resilient stocks with low risk scores and seeing which companies carry sturdier risk profiles than many headline names.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com